ESP-01 is under clinical development by Esperas Pharma and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase II drugs for Endometrial Cancer have a 22% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ESP-01’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ESP-01 overview

ESP-01 is under development for the treatment of solid tumours including metastatic colorectal cancer, epithelial ovarian cancer, endometrial cancer, ewing sarcoma, soft tissue sarcoma, gastrointestinal stromal tumors (GIST), pancreatic cancer and triple-negative breast cancer (TNBC). It is administered by the oral route. The drug candidate acts by targeting checkpoint Kinase 1 (CHK 1).

For a complete picture of ESP-01’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.